阿替利珠单抗联合维莫非尼和考比替尼治疗BRAFV600突变阳性黑色素瘤的治疗获益生物标志物
III期IMspire150研究纳入514例BRAFV600突变晚期黑色素瘤患者,随机分配至阿替利珠单抗+维莫非尼+考比替尼组(n=256)或安慰剂+维莫非尼+考比替尼组(n=258)。探索性生物标志物分析显示,高TMB(≥10突变/Mb)患者PFS获益HR 0.73(95%CI 0.52-1.02;P=0.067),LDH升高且PD-L1阴性亚组HR 0.53(95%CI 0.29-0.95;P=0.032)。
要点
- 高TMB(≥10突变/Mb)患者阿替利珠单抗组PFS的HR为0.73(95%CI 0.52-1.02;P=0.067)。
- LDH升高患者中,PD-L1阴性亚组阿替利珠单抗组PFS的HR为0.53(95%CI 0.29-0.95;P=0.032)。
- LDH升高且PD-L1阳性亚组阿替利珠单抗组PFS的HR为1.16(95%CI 0.75-1.80;P=0.51)。
核心结论
- 阿替利珠单抗组的治疗获益似乎在LDH升高且PD-L1阴性肿瘤患者中最为明显。
- 无论治疗如何,LDH仍是结局的主要预测因素。
- IFN-γ和TMB进一步区分接受阿替利珠单抗联合维莫非尼和考比替尼治疗患者的结局。
研究设计与样本
- III期IMspire150研究(NCT02908672)的探索性生物标志物分析。
- 514例BRAFV600突变晚期黑色素瘤患者随机分配至阿替利珠单抗组(n=256)或对照组(n=258)。
- 按PD-L1表达、LDH水平、TMB和IFN-γ基因特征定义亚组评估结局。
- 采用探索性递归 partitioning 分析建模PFS与基线协变量的关联。
主要发现
- 高TMB(≥10突变/Mb)患者阿替利珠单抗组 vs 对照组PFS的HR为0.73(95%CI 0.52-1.02;P=0.067)。
- 低TMB(<10突变/Mb)患者阿替利珠单抗组 vs 对照组PFS的HR为0.92(95%CI 0.65-1.30;P=0.64)。
- 强IFN-γ(≥中位数)患者阿替利珠单抗组 vs 对照组PFS的HR为0.76(95%CI 0.54-1.06)。
- 弱IFN-γ(<中位数)患者阿替利珠单抗组 vs 对照组PFS的HR为0.79(95%CI 0.58-1.08)。
- LDH升高患者中,PD-L1阴性亚组阿替利珠单抗组 vs 对照组PFS的HR为0.53(95%CI 0.29-0.95;P=0.032),PD-L1阳性亚组HR为1.16(95%CI 0.75-1.80;P=0.51)。
关键数值与推荐
- 高TMB定义为≥10突变/Mb,低TMB定义为<10突变/Mb。
- IFN-γ强/弱以中位数为界。
- 递归 partitioning 分析显示,在阿替利珠单抗组中,IFN-γ可区分LDH正常患者的PFS结局,而TMB可区分LDH升高患者的PFS结局。
- 在对照组中,IFN-γ和TMB均不能区分PFS结局。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The phase III IMspire150 study (NCT02908672) demonstrated significantly improved progression-free survival (PFS) with atezolizumab, vemurafenib, and cobimetinib (atezolizumab group) versus placebo, vemurafenib, and cobimetinib (control group) in patients with BRAFV600-mutated advanced melanoma. We report exploratory biomarker analyses to optimize targeting of patients who are more likely to benefit from triplet combination therapy. PATIENTS AND METHODS: Five hundred fourteen patients were randomized to atezolizumab (n = 256) or control (n = 258). Outcomes were evaluated in subgroups defined by key biomarkers, including programmed death-ligand 1 (PD-L1) expression, lactate dehydrogenase (LDH) level, tumor mutational burden (TMB), and interferon-γ (IFN-γ) gene signature. Exploratory recursive partitioning analysis was then used to model associations between PFS and baseline covariates, including key biomarkers. RESULTS: PFS benefit for atezolizumab versus control was greater in patients with high TMB [≥10 mutations/Mb; hazard ratio (HR) 0.73; 95% confidence interval (CI) 0.52-1.02; P = 0.067] versus low TMB (<10 mutations/Mb; HR 0.92; 95% CI 0.65-1.30; P = 0.64) and similar between patients with strong IFN-γ (≥median; HR 0.76; 95% CI 0.54-1.06) versus weak IFN-γ (<median; HR 0.79; 95% CI 0.58-1.08). In patients with elevated LDH, PFS benefit for atezolizumab versus control was greater in the PD-L1- subgroup (HR 0.53; 95% CI 0.29-0.95; P = 0.032) than in the PD-L1+ subgroup (HR 1.16; 95% CI 0.75-1.80; P = 0.51). Recursive partitioning analysis showed that IFN-γ discriminated PFS outcomes in patients with normal LDH, whereas TMB discriminated outcomes in patients with elevated LDH in the atezolizumab group. Neither IFN-γ nor TMB discriminated PFS outcomes in the control group. CONCLUSIONS: Treatment benefits in the atezolizumab group seemed to be most evident in patients with elevated LDH and PD-L1- tumors. LDH remains the primary predictor of outcomes regardless of treatment. IFN-γ and TMB further differentiate outcomes for patients treated with atezolizumab, vemurafenib, and cobimetinib.
引用
- Robert C, Lewis KD, Gutzmer R, et al. Biomarkers of treatment benefit with atezolizumab plus vemurafenib plus cobimetinib in BRAFV600 mutation-positive melanoma. Ann Oncol. 2022. PMID: 35131452. doi:10.1016/j.annonc.2022.01.076
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。